LOGO
LOGO

Innovent Biologics, Inc (1801.HK)

  • Innovent’s IBI363 Secures Third NMPA Breakthrough Therapy Designation For Metastatic Colorectal Cancer 5/10/2026 9:12:47 PM
  • Innovent’s Partner Ollin Unveils Final Head-to-Head Data: IBI324 Vs. Faricimab In Wet AMD And DME 3/30/2026 8:42:22 PM
  • Innovent Biologics FY Revenue RMB 13.042 Bln Vs. RMB 9.422 Bln Last Year 3/26/2026 5:46:05 AM
  • Innovent’s Phase 3 STAR Study Confirms Efdamrofusp Alfa Meets Primary Endpoint In NAMD 3/23/2026 8:39:42 PM
  • Innovent Says First Participant Dosed Of IBI128 In Phase 3 Clinical Study 3/22/2026 8:34:16 PM
  • Innovent Biologics: Jaypirca Approved In China For R/R Chronic Lymphocytic Leukemia Or SLL Treatment 3/1/2026 7:42:34 PM
  • Innovent Doses First Patient In Phase 3 Trial Of IBI354 For First-Line Treatment Of HER2-Positive Breast Cancer 2/12/2026 7:56:52 PM
  • Older Articles
Copyright © 2026 RTTNews. All rights reserved. By using this site, you agree to the Terms of Service. About Us   |   Contact Us   |   Privacy   |   Sitemap